319 related articles for article (PubMed ID: 7872950)
1. Differential effects of phosphodiesterase inhibitors on accumulation of cyclic AMP in isolated ventricular cardiomyocytes.
Kelso EJ; McDermott BJ; Silke B
Biochem Pharmacol; 1995 Feb; 49(4):441-52. PubMed ID: 7872950
[TBL] [Abstract][Full Text] [Related]
2. Cardiotonic actions of selective phosphodiesterase inhibitors in rat isolated ventricular cardiomyocytes.
Kelso EJ; McDermott BJ; Silke B
Br J Pharmacol; 1993 Dec; 110(4):1387-94. PubMed ID: 8306078
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the phosphodiesterase inhibition by 2-(3-methoxy-5-methylsulfinyl-2-thienyl)-1H-imidazo-(4,5-c)-pyridine HCl and its sulfide- and sulfone derivatives in myocardial preparations from failing human hearts.
Bethke T; Klimkiewicz A; Meyer W; Schumacher C; Schmitz W; Scholz H; Starbatty J; Wenzlaff H; Zimmermann W
Arzneimittelforschung; 1995 Jul; 45(7):771-6. PubMed ID: 8573220
[TBL] [Abstract][Full Text] [Related]
4. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine.
Katano Y; Endoh M
J Cardiovasc Pharmacol; 1992; 20(5):715-22. PubMed ID: 1280732
[TBL] [Abstract][Full Text] [Related]
5. Actions of the novel vasodilator, flosequinan, in isolated ventricular cardiomyocytes.
Kelso EJ; McDermott BJ; Silke B
J Cardiovasc Pharmacol; 1995 Mar; 25(3):376-86. PubMed ID: 7769801
[TBL] [Abstract][Full Text] [Related]
6. Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity.
Shafiee-Nick R; Pyne NJ; Furman BL
Br J Pharmacol; 1995 Aug; 115(8):1486-92. PubMed ID: 8564209
[TBL] [Abstract][Full Text] [Related]
7. OPC-13013, a cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells.
Shimizu E; Kobayashi Y; Oki Y; Kawasaki T; Yoshimi T; Nakamura H
Life Sci; 1999; 64(23):2081-8. PubMed ID: 10372650
[TBL] [Abstract][Full Text] [Related]
8. Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism.
Ahn HS; Eardley D; Watkins R; Prioli N
Biochem Pharmacol; 1986 Apr; 35(7):1113-21. PubMed ID: 2421728
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors.
Souness JE; Hassall GA; Parrott DP
Biochem Pharmacol; 1992 Sep; 44(5):857-66. PubMed ID: 1326964
[TBL] [Abstract][Full Text] [Related]
10. Regulation of cyclic AMP metabolism in bovine adrenal medullary cells.
Marley PD; Thomson KA
Biochem Pharmacol; 1992 Dec; 44(11):2105-10. PubMed ID: 1335250
[TBL] [Abstract][Full Text] [Related]
11. Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis.
Torphy TJ; Zhou HL; Burman M; Huang LB
Mol Pharmacol; 1991 Mar; 39(3):376-84. PubMed ID: 1848659
[TBL] [Abstract][Full Text] [Related]
12. The role of phosphodiesterase in mediating the effect of protein kinase C on cyclic AMP accumulation upon kappa-opioid receptor stimulation in the rat heart.
Bian JS; Zhang WM; Pei JM; Wong TM
J Pharmacol Exp Ther; 2000 Mar; 292(3):1065-70. PubMed ID: 10688624
[TBL] [Abstract][Full Text] [Related]
13. Effects of the phosphodiesterase inhibitor enoximone on the autonomic innervation of the isolated heart.
Löffelholz K; Dressler H; Lindmar R
J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S33-9. PubMed ID: 2480484
[TBL] [Abstract][Full Text] [Related]
14. Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle.
Endoh M; Yanagisawa T; Taira N; Blinks JR
Circulation; 1986 Mar; 73(3 Pt 2):III117-33. PubMed ID: 2417745
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells.
Pan X; Arauz E; Krzanowski JJ; Fitzpatrick DF; Polson JB
Biochem Pharmacol; 1994 Aug; 48(4):827-35. PubMed ID: 7521642
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of sulmazole (AR-L 115 BS) on contractile force and cyclic AMP levels in canine ventricular muscle: comparison with MDL 17,043.
Endoh M; Yanagisawa T; Morita T; Taira N
J Pharmacol Exp Ther; 1985 Jul; 234(1):267-73. PubMed ID: 2989507
[TBL] [Abstract][Full Text] [Related]
17. Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3.
Delpy E; Coste H; Gouville AC
Br J Pharmacol; 1996 Oct; 119(3):471-8. PubMed ID: 8894166
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase inhibition by enoximone in preparations from nonfailing and failing human hearts.
Bethke T; Eschenhagen T; Klimkiewicz A; Kohl C; von der Leyen H; Mehl H; Mende U; Meyer W; Neumann J; Rosswag S
Arzneimittelforschung; 1992 Apr; 42(4):437-45. PubMed ID: 1386515
[TBL] [Abstract][Full Text] [Related]
19. Atrial natriuretic peptide reduces cyclic AMP by activating cyclic GMP-stimulated phosphodiesterase in vascular endothelial cells.
Kishi Y; Ashikaga T; Watanabe R; Numano F
J Cardiovasc Pharmacol; 1994 Sep; 24(3):351-7. PubMed ID: 7528289
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts.
Bethke T; Meyer W; Schmitz W; Scholz H; Stein B; Thomas K; Wenzlaff H
Br J Pharmacol; 1992 Sep; 107(1):127-33. PubMed ID: 1384905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
